PMCF Study to Evaluate Performance and Safety of "Hyaluronic Acid (HA)-Based Eyedrops" Used to Relieve Dry Eye Symptoms

Dry Eye Clinical Trial

Official title:

An Interventional, Non-comparative, Single-center Post Marketing Clinical Follow-up (PMCF) Study to Evaluate Performance and Safety of "Hyaluronic Acid (HA)-Based Eyedrops" Used to Relieve Dry Eye Symptoms.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05807360
• Other study ID #: COC-R1-HA
• Status: Completed
• Phase: N/A
• Start date: June 24, 2022
• Est. completion date: June 5, 2023

Study information

• Verified date: April 2023
• Source: C.O.C. Farmaceutici S.r.l.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Dry eye disease (DED), also called keratoconjunctivitis sicca, is a common ocular condition characterized by a loss of homeostasis of the tear film and inflammation of the ocular surface. The typical symptoms of DED include irritation, discomfort, blurred or fluctuating vision. Over the counter (OTC) artificial tears are typically the first line of dry eye treatment; they are meant to supplement the tears that cover the eye's surface. OTC products mimic the different layers of the tear film in order to maintain ocular hydration. HA is found in higher concentrations in the vitreous humor of the eye, cartilage, and the synovial fluid. As a component of the tear film, HA increases the viscosity of the tear film and hydrates and lubricates the ocular surface. HA possesses intrinsic water retention properties, viscoelasticity, and favors the healing of corneal and conjunctival epithelium. For these reasons, an interventional, non-comparative, single-center Post Marketing Clinical Follow-up (PMCF) study was planned to evaluate the performance and safety of "HA-based eyedrops" used as intended to relieve dry eye symptoms. The objectives of the PMCF study are confirmation of the performance, collection of additional safety data regarding expected adverse events and detection of potential unexpected adverse events associated with use of "HA-based eyedrops" according to the IFU. "Hyaluronic Acid (HA)-based eyedrops" are medical devices used as intended to improve the discomfort due to dry eye (for intrinsic and/or extrinsic causes), contact lenses wearing and/or eye surgery. Each Subject, after signing the Informed Consent Form, will enter the screening and baseline phase (the 2 visits will coincide) during which baseline procedures will be completed. At baseline visit (V0), one of the "Hyaluronic Acid (HA)-based eyedrops" products can be dispensed to the enrolled Subjects, depending on Investigator clinical evaluation, and severity of the disease. The patient will perform 2 on site visits (V0 and V2/EOS). To monitor the safety, 1 phone contact is planned (V1) to check for potential adverse events (AEs) and concomitant medications intake.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 160
• Est. completion date: June 5, 2023
• Est. primary completion date: June 5, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patient Informed consent form (ICF) signed;
• Male & Female Aged = 18 years at the time of the signature of the ICF;
• Patients with ophthalmic discomfort due to dry eye for intrinsic and/or extrinsic causes, contact lenses wearing and/or eye surgery;
• WIlling not to use other eye drops during the entire treatment period.

Exclusion Criteria:

• Other - different - eyes clinical conditions (e.g. glaucoma);
• Suspected alcohol or drug abuse;
• Known hypersensitivity or allergy to IP components;
• Other clinically significant and uncontrolled pathologies that may interfere with study results (e.g. rheumatic diseases, diabetes);
• Participation in another investigational study;
• Inability to follow all study procedures, including attending all site visits, tests and examinations;
• Mental incapacity that precludes adequate understanding or cooperation.

Related Conditions & MeSH terms

• Conjunctivitis
• Dry Eye
• Dry Eye Disease
• Dry Eye Syndromes
• Eye Diseases
• Kerato Conjunctivitis Sicca
• Keratoconjunctivitis
• Keratoconjunctivitis Sicca

Intervention

Device:
• Hyaluronic acid eye drops
Hyaluronic acid (HA)-based eyedrops

Locations

Country	Name	City	State
Italy	Azienda Ospedaliero-Universitaria Policlinico "G.Rodolico - San Marco"	Catania	CT

Sponsors (1)

Lead Sponsor	Collaborator
C.O.C. Farmaceutici S.r.l.

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Schirmer Test I: to evaluate the performance of the "HA-based eyedrops" used to relieve dry eye symptoms due to both intrinsic and extrinsic causes, through Schirmer I test		From Baseline (V0 = Day 0) at 1 month (EOS/V2 = Day 30)
Secondary	Change in Ocular Surface Disease Index (OSDI): to evaluate the performance of the "HA-based eyedrops" used to relieve eye discomfort sensation		From Baseline (V0 = Day 0) at 1 month (EOS/V2 = Day 30)
Secondary	Change in Tear Break-up Time (TBUT): to evaluate the performance of the "HA-based eyedrops" used to relieve ophthalmic stress due to prolonged use of contact lenses or surface eye surgery, through the TBUT test		From Baseline (V0 = Day 0) at 1 month (EOS/V2 = Day 30)
Secondary	To evaluate the safety and tolerability of the "HA-based eyedrops" through Visual Analogical Scale (VAS) - evaluation of symptoms related to dry eye disease (burning, fatigue, discomfort, redness)	Visual Analogical Scale Minimum value = 0 Maximum value = 10 Higher scores mean a better outcome	End of study visit (EOS/V2 = Day 30)
Secondary	To evaluate the patient satisfaction of the "HA-based eyedrops" through a 5-points Likert Scale		End of study visit (EOS/V2 = Day 30)